Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,719 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use.
Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R. Patel M, et al. J Allergy Clin Immunol. 2012 Dec;130(6):1420-2. doi: 10.1016/j.jaci.2012.06.037. Epub 2012 Aug 22. J Allergy Clin Immunol. 2012. PMID: 22920492 No abstract available.
Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians.
Chan AH, Harrison J, Black PN, Mitchell EA, Foster JM. Chan AH, et al. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):335-49.e1-5. doi: 10.1016/j.jaip.2015.01.024. Epub 2015 Apr 1. J Allergy Clin Immunol Pract. 2015. PMID: 25840665 Review.
Risk factors for asthma at 3.5 and 7 years of age.
Mitchell EA, Robinson E, Black PN, Becroft DM, Clark PM, Pryor JE, Thompson JM, Waldie KE, Wild CJ. Mitchell EA, et al. Clin Exp Allergy. 2007 Dec;37(12):1747-55. doi: 10.1111/j.1365-2222.2007.02847.x. Epub 2007 Oct 10. Clin Exp Allergy. 2007. PMID: 17927798
Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial.
Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, Weatherall M, Beasley R. Patel M, et al. J Allergy Clin Immunol Pract. 2013 Jan;1(1):83-91. doi: 10.1016/j.jaip.2012.08.004. Epub 2012 Nov 2. J Allergy Clin Immunol Pract. 2013. PMID: 24229826 Clinical Trial.
Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
Patel M, Pilcher J, Reddel HK, Qi V, Mackey B, Tranquilino T, Shaw D, Black P, Weatherall M, Beasley R; SMART Study Group. Patel M, et al. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):751-8. doi: 10.1016/j.jaip.2014.06.001. Epub 2014 Jul 25. J Allergy Clin Immunol Pract. 2014. PMID: 25439367 Clinical Trial.
Short-acting β-agonist use as a marker of current asthma control.
Patel M, Pilcher J, Munro C, Hosking A, Pritchard A, Shaw D, Black P, Weatherall M, Beasley R; SMART Study Group. Patel M, et al. J Allergy Clin Immunol Pract. 2013 Jul-Aug;1(4):370-7. doi: 10.1016/j.jaip.2013.04.008. Epub 2013 Jun 5. J Allergy Clin Immunol Pract. 2013. PMID: 24565542 Clinical Trial.

RESULTS: The number of days of albuterol use, the average number of albuterol actuations/day, and the highest number of albuterol actuations/day in the 1-week period were all positively associated with ACQ-5 score (r = 0.41-0.45, P < .001) and had moderate discriminatio

RESULTS: The number of days of albuterol use, the average number of albuterol actuations/day, and the highest number of albuterol actuations …
Metrics of salbutamol use as predictors of future adverse outcomes in asthma.
Patel M, Pilcher J, Reddel HK, Pritchard A, Corin A, Helm C, Tofield C, Shaw D, Black P, Weatherall M, Beasley R; SMART Study Group. Patel M, et al. Clin Exp Allergy. 2013 Oct;43(10):1144-51. doi: 10.1111/cea.12166. Clin Exp Allergy. 2013. PMID: 24074332 Clinical Trial.
Electronic adherence monitoring device performance and patient acceptability: a randomized control trial.
Chan AHY, Stewart AW, Harrison J, Black PN, Mitchell EA, Foster JM. Chan AHY, et al. Expert Rev Med Devices. 2017 May;14(5):401-411. doi: 10.1080/17434440.2017.1322505. Epub 2017 May 3. Expert Rev Med Devices. 2017. PMID: 28434269 Clinical Trial.
Acceptability scores were high, with higher scores in the reminder than non-reminder group (median, 5(th)-95(th) percentile: 4.1, 3.1-5.0 versus 3.7, 2.3-4.8; p < 0.001). ...
Acceptability scores were high, with higher scores in the reminder than non-reminder group (median, 5(th)-95(th) percentile: 4.1, 3.1-5.0 ve …
A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial.
Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, Purdie G, Crane J; Probiotic Study Group. Wickens K, et al. J Allergy Clin Immunol. 2008 Oct;122(4):788-794. doi: 10.1016/j.jaci.2008.07.011. Epub 2008 Aug 31. J Allergy Clin Immunol. 2008. PMID: 18762327 Clinical Trial.
RESULTS: Infants receiving L rhamnosus had a significantly (P = .01) reduced risk of eczema (hazard ratio [HR], 0.51; 95% CI, 0.30-0.85) compared with placebo, but this was not the case for B animalis subsp lactis (HR, 0.90; 95% CI, 0.58-1.41). ...
RESULTS: Infants receiving L rhamnosus had a significantly (P = .01) reduced risk of eczema (hazard ratio [HR], 0.51; 95% CI, 0.30-0. …
A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.
Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, Purdie G, Crane J. Wickens K, et al. Clin Exp Allergy. 2012 Jul;42(7):1071-9. doi: 10.1111/j.1365-2222.2012.03975.x. Clin Exp Allergy. 2012. PMID: 22702506 Clinical Trial.
1,719 results
Jump to page
Feedback